Stada Group
Deniz Simseker has a diverse work experience spanning various industries and roles. Deniz currently holds the position of Vice President of Global Internal Audit at the STADA Group since January 2021. Prior to this, they worked at Merz Pharma GmbH & Co. KGaA, where they served as the Executive Director and Head of Group Internal Audit from July 2020 to December 2020, and as the Senior Director and Head of Global Internal Audit from July 2017 to June 2020.
Before joining Merz Pharma, Deniz worked at Sanofi as a Senior Manager CFO for Emerging Markets CHC from January 2017 to June 2017. Prior to this, they held various roles at Boehringer Ingelheim, including Senior Manager CFO for Emerging Markets CHC from August 2014 to December 2016, Team Leader of Corporate Auditing from February 2014 to July 2014, and Senior Manager of Corporate Audit from June 2011 to February 2014.
Deniz'searlier professional experience includes working as a Corporate Audit Team Leader at Clariant from March 2007 to May 2011, as a Senior at EY from October 2004 to February 2007, and as a Consultant at Arthur Andersen Business Consulting from January 2002 to September 2004. Deniz began their career as a Business Case Analyst at Opel from July 2001 to December 2001.
Deniz Simseker holds a Master's degree in Business Administration and Management with a focus on Finance from Johannes Gutenberg Universität Mainz.
This person is not in any offices
Stada Group
14 followers
Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and active-ingredient products. The Branded Products segment focuses on multisource products accessible without active ingredient research, notably anti-enzymatic food intolerance drugs that are marketed by the subsidiary SCIOTEC Diagnostics Technologies. The Company's generic drugs are marketed by the Group subsidiary, STADApharm GmbH. Non-core activities of the Company encompass Commercial Business segment, which includes activities with primarily trading character such as wholesaling activities. The Company operates STADA Pharmaceuticals Australia Pty Ltd and STADA IT SOLUTIONS DOO as subsidiaries.